CyDex, Inc. Announces First U.S. Approval of a CAPTISOL-Enabled(TM) Medication

    OVERLAND PARK, Kan., June 10 /PRNewswire/ -- CyDex, Inc., an innovator in
 drug delivery technologies, today announced the first U.S. regulatory approval
 of a CAPTISOL-Enabled(TM) drug -- the intravenous form of Vfend(R)
 (voriconazole), a new antifungal from Pfizer Inc. CAPTISOL(R) is an advanced
 formulation system that improves the solubility, stability and bioavailability
 of drug compounds.
     "Receiving the first FDA approval for a drug using CAPTISOL(R) is a major
 milestone for CyDex and a demonstration of the value of our technologies,"
 said Peter Higuchi, President and CEO of CyDex.  "Pfizer is a wonderful
 partner, and we congratulate our colleagues on bringing Vfend to market as an
 innovative new therapy for patients with life-threatening fungal infections."
     Pfizer received clearance from the U.S. Food and Drug Administration for
 oral and intravenous use of Vfend in the primary treatment of  acute invasive
 aspergillosis and salvage therapy for rare but serious fungal infections
 caused by the pathogens Scedosporium apiospermum and Fusarium spp.  The
 intravenous Vfend formulation combines the active ingredient voriconazole with
 CAPTISOL, a proprietary CyDex molecule designed to improve the solubility of
 active drug ingredients.
     Pfizer licensed CAPTISOL from CyDex in 1993 for use in formulations of
 antifungals and other potential new drugs.  Vfend was also recently approved
 in Europe, and a second CAPTISOL-Enabled compound developed by Pfizer also is
 progressing through registration.
     CAPTISOL enables the safe, effective delivery of medications by improving
 the solubility, stability and bioavailability of drug compounds.  CAPTISOL is
 a donut-shaped molecule that complexes water insoluble active drugs in its
 central cavity.  When given by injection, a CAPTISOL-Enabled formulation helps
 carry a drug into the patient's bloodstream, where CAPTISOL and the drug
 disassociate, allowing the active ingredient to produce its desired
 pharmacological effect.
     CyDex, Inc., provides innovative drug delivery solutions to pharmaceutical
 and biotechnology companies and also is commercializing its own pipeline of
 proprietary drug candidates.  Besides Pfizer, CyDex has collaborations with
 Allergan, Inc.; Bristol-Myers Squibb; Daiichi Pharmaceutical Co., Ltd., of
 Japan; Genentech Inc.; OSI Pharmaceuticals, Inc; PTC Pharma AG, of
 Switzerland; and Suntory Ltd., of Japan.  The CAPTISOL drug delivery
 technology arises from sulfobutylether beta-cyclodextrins originally
 synthesized and patented by scientists at the University of Kansas Higuchi
 Biosciences Center for Drug Delivery Research.  CyDex is a privately owned
 company in suburban Kansas City.  Learn more at www.cydexinc.com .
 
     CAPTISOL is a registered trademark and CAPTISOL-Enabled has been filed as
 a trademark of CyDex, Inc.
     VFEND is a registered trademark of Pfizer Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X62316651
 
 

SOURCE CyDex, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.